Welcome to our dedicated page for Iqvia Hldgs SEC filings (Ticker: IQV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The IQVIA Holdings Inc. (NYSE: IQV) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports on Form 8-K and other documents filed with the U.S. Securities and Exchange Commission. IQVIA’s filings confirm that its common stock is registered under Section 12(b) of the Securities Exchange Act of 1934 and trades on the New York Stock Exchange under the symbol IQV.
IQVIA uses Form 8-K to report material events such as quarterly financial results, amendments to its credit agreements and leadership or board changes. For example, the company has filed 8-K reports describing financial results for specific quarters, an amendment to its Fifth Amended and Restated Credit Agreement and the planned transition of its chief financial officer. Other 8-K filings cover the appointment of new directors and related governance matters.
For investors analyzing IQVIA, these filings help explain the company’s financial condition, capital structure and key corporate developments. They also provide context for IQVIA’s role as a global provider of clinical research services, commercial insights and healthcare intelligence, including how it finances its operations and manages governance and leadership transitions.
On Stock Titan, SEC filings for IQVIA are updated as new documents are posted to the SEC’s EDGAR system. AI-powered summaries help interpret lengthy filings by highlighting important sections, such as descriptions of material agreements, financial updates or changes in executive roles. Users can review 8-Ks for event-driven information and refer to other filing types, such as annual and quarterly reports when available, to gain a more complete view of IQVIA’s business and risks.
IQVIA Holdings Inc. (IQV) filed a Form 4 showing that Senior Vice President & Corporate Controller Keriann Cherofsky sold 549 common shares on 07/23/2025 at $191.53 per share, a transaction valued at roughly $105k. After the sale, her direct ownership stands at 2,910 shares; no derivative securities were involved.
The disposition reduced her direct stake by about 16% (549 of ~3,459 prior shares). While small relative to IQV’s market capitalization and daily trading volume, insider sales can be perceived as a modestly bearish signal because executives possess superior insight into company prospects. No accompanying purchases, option exercises, or material company events were reported in this filing.
IQVIA Holdings Inc. (IQV) – Form 144 filing discloses a proposed insider sale of common stock under Rule 144.
- Securities offered: 5,800 common shares
- Estimated market value: $1,102,262.16 (≈ $190 per share)
- Broker: Morgan Stanley Smith Barney LLC, New York
- Planned sale date: 23 Jul 2025 on the NYSE
- Total shares outstanding: 170 million; proposed sale equals <0.01% of float
- Source of shares: Stock Appreciation Rights acquired on 23 Jul 2025; consideration paid in cash
The filer states no material non-public adverse information is known. No other sales were made in the past three months. Given the small size relative to IQVIA’s float and the absence of accompanying operational data, the notice is unlikely to affect valuation or liquidity materially.